270
Views
6
CrossRef citations to date
0
Altmetric
Original Research

CHADS2 score has a better predictive value than CHA2DS2-VASc score in elderly patients with atrial fibrillation

, , , , &
Pages 941-946 | Published online: 14 Jul 2016

Abstract

Aim

The study aims to compare the ability of CHA2DS2-VASc (defined as congestive heart failure, hypertension, age ≥75 years [two scores], type 2 diabetes mellitus, previous stroke, transient ischemic attack, or thromboembolism [TE] [doubled], vascular disease, age 65–74 years, and sex category) and CHADS2 (defined as congestive heart failure, hypertension, age ≥75 years, type 2 diabetes mellitus, previous stroke [doubled]) scores to predict the risk of ischemic stroke (IS) or TE among patients with nonvalvular atrial fibrillation (NVAF).

Methods

A total of 413 patients with NVAF aged ≥65 years, and not on oral anticoagulants for the previous 6 months, were enrolled in the study. The predictive value of the CHA2DS2-VASc and CHADS2 scores for IS/TE events was evaluated by the Kaplan–Meier method.

Results

During a follow-up period of 1.99±1.29 years, 104 (25.2%) patients died and 59 (14.3%) patients developed IS/TE. The CHADS2 score performed better than the CHA2DS2-VASc score in predicting IS/TE as assessed by c-indexes (0.647 vs 0.615, respectively; P<0.05). Non-CHADS2 risk factors, such as vascular disease and female sex, were not found to be predictive of IS/TE (hazard ratio 1.518, 95% CI: 0.832–2.771; hazard ratio 1.067, 95% CI: 0.599–1.899, respectively). No differences in event rates were found in patients with the CHADS2 scores of 1 and 2 (7.1% vs 7.8%). It was observed that patients with a CHADS2 score of ≥3 were most in need of anticoagulation therapy.

Conclusion

In patients with NVAF aged ≥65 years, the CHADS2 score was found to be significantly better in predicting IS/TE events when compared to the CHA2DS2-VASc score. Patients with a CHADS2 score of ≥3 were associated with high risk of IS/TE events.

Background

Atrial fibrillation (AF) is a common cardiac rhythm disorder, which is responsible for substantial morbidity and mortality. The prevalence of nonvalvular atrial fibrillation (NVAF) increases with advancing age and is considered to be an important risk factor for ischemic stroke (IS) and thromboembolism (TE).Citation1 Anticoagulation is the cornerstone for AF management. However, various studies have reported the underuse of oral anticoagulation (OAC) among elderly patients with NVAF,Citation2Citation4 and the situation is more grim in the People’s Republic of China.Citation5

Both CHADS2 (defined as congestive heart failure, hypertension, age ≥75 years, type 2 diabetes mellitus [DM], previous stroke [doubled]) and CHA2DS2-VASc (defined as congestive heart failure, hypertension, age ≥75 years [two scores], type 2 diabetes mellitus, previous stroke, transient ischemic attack [TIA], or TE [doubled], vascular disease, age 65–74 years, and sex category) scores are well-validated tools for the estimation of stroke risk in patients with AF. CHA2DS2-VASc improves the precision of identifying “low-risk” patients.Citation6 Age is a very important factor of stroke, and it is unclear which score is better suited for use in elderly patients.Citation7 The goal of the present study was to compare the utility of CHA2DS2-VASc and CHADS2 scores in predicting IS/TE for the patients with NVAF aged ≥65 years.

Methods

Ethical approval was obtained from the Hospital Ethical Committee of Beijing Friendship Hospital. A procedure-oriented informed consent form was signed by each patient. A retrospective study was conducted by collecting patient data available at Beijing Friendship Hospital for the period between January 1, 2011, and June 30, 2013. It was possible to retrieve the data pertaining to individual patients as all data at our hospital are linked to a unique, permanent, and personal registration number, which is assigned to every patient. Patients with NVAF aged ≥65 years, and not on OAC for the previous 6 months, were enrolled in the study. Diagnosis of AF was based on electrocardiography (12-lead electrocardiography) or 24-hour Holter monitoring. Patients with valvular AF, rheumatic mitral stenosis, mechanical or bioprosthetic heart valve, and mitral valve repair and those receiving hemodialysis or on OAC were excluded from the study.

The study consisted of baseline and follow-up periods. The date of the qualifying AF diagnosis made between January 1, 2011, and June 30, 2013, was designated as the index date. Data from the baseline period, which ended on the index date, were used to obtain information about each patient’s medical history. Follow-up was performed by going through medical records available in the hospital database. Data from the follow-up period, which started from the day after the index date and ended on March 1, 2015, were used to assess the risk of IS/TE. All patients who were lost to follow-up and those who took OAC during the study period were excluded.

The primary end point was the development of IS or TE events (ie, TIA or peripheral embolism). The secondary end point was all-cause death.

IS was defined as a new, sudden focal neurological deficit resulting from a presumed cerebrovascular cause that persisted >24 hours and was not attributable to other identifiable causes, such as tumor and seizure. Events that involved symptoms that lasted <24 hours were considered as TIA. Brain imaging was sought in each case to distinguish hemorrhagic from IS. Peripheral artery embolism was defined as abrupt vascular insufficiency associated with clinical or radiographic evidence of peripheral arterial occlusion in the absence of other likely causes. Presence of vascular disease was identified from previous diagnoses, including myocardial infarction (MI), peripheral artery disease, and complex aortic plaque.

Data were expressed as mean ± SD. The analyses were performed using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA), except net reclassification improvement (NRI), which was analyzed using SAS9.2. Mean values and proportions of variables were compared using unpaired Student’s t-test, analysis of variance, and chi-square test. The IS/TE risk was assessed using Cox regression analysis. The cumulative incidence curve of IS/TE was plotted via the Kaplan–Meier method, with statistical significance examined using the log-rank test. We assessed the predictive accuracies of the CHADS2 and CHA2DS2-VASc scores by calculating c-indices on the basis of receiver operating characteristic (ROC) curves and NRI. Areas under the ROC curves for these two scoring systems were compared using DeLong’s test. Statistical significance was defined as a P-value of <0.05.

Results

Characteristics of patients

Baseline characteristics of the study population are listed in . The mean age of patients was 80.82±7.34 years, with 70.9% being male. The median score of CHA2DS2-VASc and CHADS2 was 4.77 and 2.95, respectively. Hypertension was the most prevalent comorbidity and was noted in 77.5% of patients. A total of 36.8% had a history of previous stroke or TIA. During the follow-up period of 1.99±1.29 years, 104 (25.2%) patients died and 59 (14.3%) patients had an IS/TE event.

Table 1 Baseline characteristics of patients with AF by CHADS2 scores

On the basis of the CHADS2 score, 1.7%, 10.2%, and 86.3% of patients were classified as low risk (0 point), intermediate risk (1 point), and high risk (2–6 points), respectively.

Comparison between CHADS2 and CHA2DS2-VASc scores

Both the CHADS2 and CHA2DS2-VASc scores were the significant predictors of IS after adjusting for age and sex. Cox regression model improved from 1.286 (95% CI: 1.086–1.523) to 1.438 (95% CI: 1.187–1.743) when the CHADS2 score was used for stroke risk categorization instead of the CHA2DS2-VASc score.

Of the components of CHADS2 and CHA2DS2-VASc scores, cardiac failure and previous stroke/TIA were strongly associated with the primary end point (hazard ratio [HR] 2.253, 95% CI: 1.240–4.092; HR 2.555, 95% CI: 1.408–4.635, respectively). Age was also found to be associated with IS/TE during follow-up. However, hypertension, DM, vascular disease, and female sex were not found to be predictive of IS/TE ( and ). Among patients with the vascular disease, peripheral arterial disease significantly increased the risk of stroke by 2.71-fold. Previous MI was not a significant predictor of IS/TE.

Table 2 IS/TE risk of CHADS2 components from Cox regression analyses

Table 3 IS/TE risk of CHA2DS2-VASc components from Cox regression analyses

shows the ROC curves of CHADS2 and CHA2DS2-VASc scores in predicting IS/TE. The c-indices on the basis of area under the ROC curves for the CHADS2 and CHA2DS2-VASc scores were 0.647 (95% CI: 0.599–0.693) and 0.615 (95% CI: 0.566–0.662), respectively. The difference was statistically significant in favor of the CHADS2 score (DeLong’s test, P-value =0.0498–0.05, NRI =0.237). The cut-off value of CHADS2 score was 2.5, with a specificity of 0.537 and a sensitivity of 0.780.

Figure 1 ROC curves of CHADS2 and CHA2DS2-VASc scores in predicting IS/TE.

Notes: CHADS2 < congestive heart failure, hypertension, age ≥75 years, type 2 DM, previous stroke (doubled); CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years (two scores), type 2 DM, previous stroke, TIA, or TE (doubled), vascular disease, age 65–74 years, and sex category.
Abbreviations: DM, diabetes mellitus; IS, ischemic stroke; ROC, receiver operating characteristic; TE, thromboembolism; TIA, transient ischemic attack.
Figure 1 ROC curves of CHADS2 and CHA2DS2-VASc scores in predicting IS/TE.

CHADS2 score of ≥3 identified a true high-risk cohort

The Kaplan–Meier curve of freedom from IS is shown in . Patients with a CHADS2 score of 0 had no stroke event. Patients with a CHADS2 score of 2 had a similar event rate to those with a CHADS2 score of 1 during the follow-up period (7.1% vs 7.8%; P=0.887). Compared with a CHADS2 score of 1, patients with a CHADS2 score of 3, 4, 5, or 6 had a higher event rate (14.4%, 23.1%, 24.4%, and 10%, respectively).

Figure 2 The Kaplan–Meier curve of freedom from ischemic stroke by CHADS2 score.

Note: CHADS2 < congestive heart failure, hypertension, age ≥75 years, type 2 DM, previous stroke (doubled).
Abbreviation: DM, diabetes mellitus.
Figure 2 The Kaplan–Meier curve of freedom from ischemic stroke by CHADS2 score.

Using a CHADS2 score of 1 as the reference in the Cox regression analysis model, the HRs associated with the CHADS2 scores of 2, 3, 4, 5, and 6 were 1.09, 2.02, 3.32, 3.42, and 1.40, respectively (). The event rates with the CHADS2 scores of 1, 2, 3, 4, 5, and 6 were 7.14%, 7.81%, 14.44%, 23.08%, 20%, and 10%, respectively. These findings indicated that a CHADS2 score of 2 had a similar event rate to a CHADS2 score of 1, and CHADS2 score ≥3 identified a cohort with a true high risk. The HR of the group with a CHADS2 score of 6 was 1.40, perhaps because of its small size.

Figure 3 Risk of IS/TE based on CHADS2 scores.

Note: CHADS2, congestive heart failure, hypertension, age ≥75 years, type 2 DM, previous stroke (doubled).
Abbreviations: DM, diabetes mellitus; IS, ischemic stroke; TE, thromboembolism; M–H, Mantel–Haenszel test.
Figure 3 Risk of IS/TE based on CHADS2 scores.

Discussion

CHA2DS2-VASc is reported to be better than the CHADS2 score in identifying the true low-risk patients.Citation8Citation12 However, for the regions and population where OAC is frequently underused, it is more important to identify the true high-risk patients. The underuse of OAC among elderly patients with NVAF has been confirmed in different settings.Citation2Citation4 One of the most important reasons is that the treating physicians are not sure about which scoring system to follow to determine which patient requires the OAC the most. Therefore, it is necessary to compare the predictive value of two scores, CHA2DS2-VASc and CHADS2, in predicting IS among patients diagnosed with NVAF aged ≥65 years, and to find patients with a true high risk.

In the present study, we only included patients aged 65 years or older. This implies that every patient was added at least 1 point by the CHA2DS2-VASc system, and that both CHADS2 and CHA2DS2-VASc scores were useful parameters for predicting adverse events in patients with NVAF aged ≥65 years. However, the CHADS2 score was found to be more appropriate for patients aged ≥65 years for the categorization of stroke risk when compared with the CHA2DS2-VASc score. A CHADS2 score of ≥3 identified patients with a true high risk. Consistent with the findings of our study, Friberg et alCitation13 found that the risk of IS in patients with a CHA2DS2-VASc score of 1 seemed to be lower than previously reported (0.1%–0.7%).

In the present study, cardiac failure, age, and history of previous stroke were found to be the independent predictors of IS/TE. Although vascular disease and female sex were not associated with IS/TE risk, both are the additional “non-CHADS2” risk factors that are incorporated into the CHA2DS2-VASc score as per 2012 European Society of Cardiology guidelines.Citation14

Several studies have been conducted to assess the impact of atherosclerotic vascular disease on stroke in patients with AF. Peripheral arterial disease significantly increased the risk of stroke in all observational studies with the reported risk ranging from 1.3-fold to 2.5-fold.Citation15,Citation16 Complex aortic plaque in the descending aorta has also been reported as a significant risk factor.Citation17Citation19 However, there is no conclusive evidence that previous MI is a predictor of IS.Citation20 In our study, vascular disease included previous MI and peripheral arterial disease. We found peripheral arterial disease to significantly increase the risk of stroke by 2.71-fold. Previous MI was not a significant predictor of IS/TE, which is consistent with the findings of Lin et al.Citation21

Though female sex is another “non-CHADS2” risk factor and has been reported to be associated with IS/TE in patients with AF,Citation22,Citation23 the said association is considered as controversial. Various studies have reported that female sex is associated with an increased risk of stroke in only those patients with AF aged ≥75 years, whereas female patients aged <65 years without other risk factors do not require anti-coagulation therapy.Citation24,Citation25 Moreover, most of the clinical trials supporting female sex as a risk factor are from the western countries. However, studies conducted in the eastern countries have not reported similar results.Citation26 It has been reported that female sex increases the risk for their comorbidities, such as heart and renal failures.Citation22 In our study, which enrolled patients aged ≥65 years, there was no significant difference in the rate of hypertension, previous stroke/TIA, DM, and CHF in females when compared with males (73.4% vs 75.5%, 39.1% vs 37.7%, 37.5% vs 34.3%, and 23% vs 22.5%, respectively). In addition, the rate of IS/TE in females was not found to be significantly different from males (13.4% vs 14.6%; P>0.05). Therefore, in-line with other studies, the findings of our study indicate that female sex need not be considered when deciding on the antithrombotic therapy.Citation27

In our study, the cut-off value for a very high risk of stroke when using the CHADS2 score was 3, which was determined by ROC curve analysis. In fact, the event rates during the follow-up period among patients with the CHADS2 scores of 1 and 2 were almost the same (7%), thus indicating intermediate risk in the CHADS2 score of 1. Both the CHADS2 scores of 1 and 2 need OAC.

It is important to note the limitations of our study. Being a retrospective analysis, follow-up was performed by assessing medical records available in the hospital database only, hence some clinically relevant events may have been missed. The study had a limited number of patients, especially in the group of CHADS2 scores 0 and 9. The HR associated with a CHADS2 score of 6 (relative risk [RR] =1.4 [95% CI {0.16–12.09}]) is considerably lower than that with a CHADS2 score of RR =5 (3.42, 95% CI [1.03–12.42]). for the size of sample. We will enlarge the sample in the future.

Conclusion

For patients with NVAF aged 65 years or older, both vascular disease and female sex were not the predictors of IS/TE risk. The use of the CHADS2 score significantly improves the classification of patients with AF at high risk of stroke compared with the CHA2DS2-VASc score. Thus, future large-scale studies involving multiple centers are needed to further corroborate our findings.

Acknowledgments

This study was supported by Beijing Health Care Research Fund (J 09-04), Basic and Clinical Research Cooperation Fund, and Capital Medical University (13JL57).

Disclosure

The authors report no conflicts of interest in this work.

References

  • LinHJWolfPAKelly-HayesMStroke severity in atrial fibrillation. The Framingham StudyStroke19962710176017648841325
  • MarcucciMIorioANobiliAFactors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wardsEur J Intern Med201021651652321111937
  • TulnerLRVan CampenJPKuperIMReasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive studyDrugs Aging2010271395020030431
  • ScowcroftACLeeSMantJThromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000–2009Heart201399212713223086966
  • ZhouZHuDAn epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland ChinaJ Epidemiol200818520921618776706
  • LipGYNieuwlaatRPistersRLaneDACrijnsHJRefining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillationChest2010137226327219762550
  • ZhuWGXiongQMHongKMeta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulationTex Heart Inst J201542161525873792
  • OlesenJBLipGYHansenMLValidation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort studyBMJ2011342d12421282258
  • PotparaTSPolovinaMMLicinaMMMarinkovicJMProstranMSLipGYReliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: the Belgrade atrial fibrillation studyCirc Arrhythm Electrophysiol20125231932622319004
  • ChaoTFLiuCJChenSJAtrial fibrillation and the risk of ischemic stroke: does it still matter in patients with a CHA2DS2-VASc score of 0 or 1?Stroke201243102551255522871677
  • LipGYFrisonLHalperinJLLaneDAIdentifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohortStroke201041122731273820966417
  • ChaoTFLinYJTsaoHMCHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablationJ Am Coll Cardiol201158232380238522115643
  • FribergLSkeppholmMTerentABenefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1J Am Coll Cardiol201565322523225614418
  • CammAJLipGYDe CaterinaR2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm AssociationEur Heart J201233212719274722922413
  • GotoSBhattDLRotherJPrevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosisAm Heart J20081565855863863.e219061698
  • ConwayDSLipGYComparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project)Am J Cardiol2004931114221425A1015165931
  • BlackshearJLPearceLAHartRGAortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implicationsStroke199930483484010187888
  • ManningWJDouglasPSTransesophageal echocardiography and atrial fibrillation: added value or expensive toy?Ann Intern Med199812886856879537943
  • ZabalgoitiaMHalperinJLPearceLABlackshearJLAsingerRWHartRGTransesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III InvestigatorsJ Am Coll Cardiol1998317162216269626843
  • AnandasundaramBLaneDAApostolakisSLipGYThe impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic reviewJ Thromb Haemost201311597598723441593
  • LinLYLeeCHYuCCRisk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation – a nation wide database analysisAtherosclerosis2011217129229521513938
  • DagresNNieuwlaatRVardasPEGender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on atrial fibrillationJ Am Coll Cardiol200749557257717276181
  • FangMCSingerDEChangYGender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) studyCirculation2005112121687169116157766
  • MikkelsenAPLindhardsenJLipGYGislasonGHTorp-PedersenCOlesenJBFemale sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort studyJ Thromb Haemost20121091745175122805071
  • WagstaffAJOvervadTFLipGYLaneDAIs female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysisQJM20141071295596724633256
  • TomitaHOkumuraKInoueHValidation of risk scoring system excluding female sex from CHA2DS2-VASc in Japanese patients with nonvalvular atrial fibrillation-subanalysis of the J-RHYTHM registryCirc J20157981719172625971525
  • VermaACairnsJAMitchellLB2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillationCan J Cardiol201430101114113025262857